SOURCE: neoSurgical

neoSurgical

August 04, 2014 09:00 ET

neoSurgical Wins R&D 100 Award for Top Technology in Advancing Port Site Closure

DUBLIN, IRELAND and CHICAGO, IL--(Marketwired - Aug 4, 2014) - neoSurgical, an international medical device company focused on advancing safer, simpler and superior solutions for laparoscopic and minimally invasive surgery (MIS), announces today that it is the recipient of a 2014 R&D 100 Award. This award recognizes neoClose™, a new trocar port closure device for laparoscopic and robotic surgery as a top technology, as determined by a select group of judges and editors from R&D Magazine for overall excellence in project team results.

"neoClose exemplifies what we look for in a winning technology as one of the 100 most significant high-technology products introduced in the past year for life sciences. I would like to commend the project team on the innovative design, development, testing and production of neoClose for advancing surgical outcomes," writes Lindsay Hock, Managing Editor of R&D Magazine.

Ronan Keating, neoSurgical's Chief Technology Officer commented, "The R&D 100 award is a great validation of the very enthusiastic response that neoClose has received from minimally invasive surgeons and the creativity of neoSurgical's R&D team and manufacturing partners. We have placed a consistent focus and commitment throughout the development cycle on facilitating simpler, superior surgery."

About neoSurgical
neoSurgical is an award winning global medical device company focused on providing technical innovation to the surgical devices industry, particularly for those surgeons conducting laparoscopic and minimally invasive surgery (MIS). Winner of the 2014 Kinetic Process Innovation Award and the R&D 100 Award, neoSurgical leverages its in-depth expertise in interpreting surgeons' needs and converting these needs via an innovative and market led engineering response to deliver compliant devices with the goal to make surgery safer, simpler and superior for both surgeons and their patients. The company's European headquarters is in Dublin with U.S. headquarters in Chicago. More information about neoSurgical can be found at: www.neosurgical.com.

Contact Information

  • Media Contact:
    Valerie Harding
    Ripple Effect Communications
    Tel: 617-536-8887
    Email: Email Contact